iCAD (NASDAQ:ICAD - Get Free Report) was downgraded by StockNews.com from a "hold" rating to a "sell" rating in a research note issued to investors on Wednesday.
iCAD Trading Down 8.0 %
NASDAQ ICAD traded down $0.29 during trading hours on Wednesday, reaching $3.32. The company's stock had a trading volume of 486,489 shares, compared to its average volume of 729,215. The business has a 50-day simple moving average of $2.37 and a 200 day simple moving average of $1.89. The stock has a market cap of $88.11 million, a PE ratio of -25.54 and a beta of 1.47. iCAD has a 52 week low of $1.18 and a 52 week high of $3.78.
Institutional Inflows and Outflows
Hedge funds have recently added to or reduced their stakes in the business. Summit Trail Advisors LLC acquired a new position in iCAD in the fourth quarter worth approximately $214,000. waypoint wealth counsel grew its holdings in shares of iCAD by 44.0% during the 4th quarter. waypoint wealth counsel now owns 14,400 shares of the technology company's stock valued at $26,000 after acquiring an additional 4,400 shares in the last quarter. Essex LLC acquired a new stake in shares of iCAD in the 3rd quarter valued at $216,000. Wells Fargo & Company MN lifted its stake in shares of iCAD by 51.3% in the 4th quarter. Wells Fargo & Company MN now owns 39,542 shares of the technology company's stock valued at $72,000 after purchasing an additional 13,402 shares during the last quarter. Finally, Integrated Wealth Concepts LLC acquired a new stake in shares of iCAD in the 4th quarter valued at $92,000. Institutional investors and hedge funds own 24.61% of the company's stock.
iCAD Company Profile
(
Get Free Report)
iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.
Featured Stories
Before you consider iCAD, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and iCAD wasn't on the list.
While iCAD currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
